Non-arteritic Anterior Ischemic Optic Neuropathy (“NAION”) is an irreversible condition that causes sudden and permanent vision loss. Plaintiffs have filed dozens of lawsuits alleging they developed NAION as a result of use of GLP-1 medications, like Ozempic, Wegovy, Saxenda, and Trulicity and that the manufacturers of these drugs knew or should have known that there was evidence of causal association between the use of GLP-1 drugs and NAION, and despite this, failed to warn of the risk.

There are now two consolidated proceedings for individuals who have suffered NAION eye injuries that are separate and distinct from the GLP-1 litigation that has been pending for two years involving gastrointestinal injuries from these drugs.

On November 10, 2025, the Supreme Court of New Jersey designated pending and future New Jersey state court actions alleging NAION injuries from use of GLP-1 prescription medications to be assigned to Superior Court Judge Gregg A. Padovano for centralized management in Bergen County. Judge Padovano will also oversee the litigation involving gastrointestinal injuries, but on a different track.

On December 15, 2025, the Judicial Panel on Multidistrict Litigation agreed to centralize action and create an MDL for Plaintiffs alleging GLP-1 drugs like Ozempic, Wegovy, Saxenda, and Trulicity caused NAION eye injuries (MDL 3163). The Panel assigned U.S. District Court Judge Karen S. Marston in the Eastern District of Pennsylvania to oversee the litigation, as she was already overseeing over 2,000 cases alleging gastrointestinal injuries following use of GLP-1 drugs (MDL 3094). The Panel found that there was a substantial degree of overlap between the NAION and gastrointestinal injuries, in that the litigation involves the same defendants and largely the same counsel as the gastrointestinal MDL 3094.

For most patients with NAION, the vision loss will not improve with time. The GLP-1 vision loss lawsuits are in the early stages of litigation.  Now that formal coordinated proceedings have been established, there will be an uptick in the number of cases filed. Pope McGlamry is filing lawsuits on behalf of individuals who took GLP-1 prescription medications and have subsequently been diagnosed with NAION in both of these coordinated proceedings. Please call 404-523-7706 to speak with one of our NAION injury attorneys for a free consultation.

Learn more about NAION and this litigation.